结直肠癌
医学
易普利姆玛
背景(考古学)
肿瘤科
内科学
无容量
佐剂
辅助治疗
癌症
病态的
临床试验
免疫疗法
生物
古生物学
作者
Alessandro Pastorino,Fabio Catalano,John Zalcberg,Alberto F. Sobrero
标识
DOI:10.1016/j.ejca.2024.113538
摘要
The remarkable outcomes achieved with neoadjuvant checkpoint inhibitors for patients diagnosed with MSI colorectal cancer hold the potential to revolutionize the treatment landscape in this context. Specifically, the combination of nivolumab plus ipilimumab in colon cancer and dostarlimab in rectal cancer has led to an unprecedented rate of complete pathological and clinical responses. Notably, these responses have been further substantiated by the absence of relapses, with a 0% relapse rate observed during the first year of follow-up. The significance of these achievements becomes even more apparent when compared to the relatively high relapse rates, ranging from 11% to 28%, observed in MSI colorectal cancer cases treated neoadjuvantly with chemo(radio)therapy. However, it is crucial to exercise caution when interpreting such exceptional responses in oncology, especially within a short follow-up period. The future implications of these findings will depend on how the data mature over time. In this manuscript, we attempt to explore the potential scenarios that may unfold in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI